However, TTI-101 treatment did not significantly affect the tumor growth in BCM-BL8091 (high SMARCB1) BLCA PDX model (Fig. 6C, D) even after 77 days of treatment. This evidence concerns the gene SMARCB1 and bladder transitional cell carcinoma.